# Upregulation of miR-4286 and miR-146a-5p in Metastatic Melanoma, Revealed by Multiplex Expression Analysis

**Authors:** Iliyan Pochileev, Albena Fakirova, Desislava Tashkova, Aleksandra Gerdgikova, Nevena Ilieva, Denitsa Serteva, Gergana Shalamanova, Hristo Ivanov, Aleksandar Linev, Ivanka Dimova

PMC · DOI: 10.3390/cimb48030279 · 2026-03-05

## TL;DR

This study identifies miR-4286 and miR-146a-5p as overexpressed microRNAs in metastatic melanoma, suggesting their potential as biomarkers or therapeutic targets.

## Contribution

The study reveals novel miRNA biomarkers in metastatic melanoma, specifically miR-4286 and miR-146a-5p, which are significantly upregulated in both BRAF wild-type and mutant tumors.

## Key findings

- 58 differentially expressed miRNAs were identified in BRAF wild-type melanoma samples.
- 37 differentially expressed miRNAs were found in BRAF mutant melanoma samples.
- miR-146a-5p and miR-4286 were the most elevated miRNAs in both melanoma groups.

## Abstract

Background: Metastatic melanoma is an extremely aggressive malignancy with limited therapeutic options, despite advances in targeted and immunotherapy. MicroRNAs are key post-transcriptional regulators of gene expression and play a critical role in tumor adaptation, invasion, and metastasis. The aim of our study was to identify dysregulated miRNAs which may serve as novel biomarkers and therapeutic targets. Materials and Methods: The study was conducted on FFPE samples from metastatic melanoma (n = 15), compared to healthy skin tissue (n = 6). BRAF V600E/Ec mutation status was established by Real-Time qPCR. Expression miRNA analysis was performed, using digital counting of 827 miRNAs on the NanoString platform, with data normalization and fold change calculations. Results: Following normalization and quality control metrics, 58 differentially expressed miRNAs were identified in BRAFwt melanoma samples: 6 overexpressed and 52 inderexpressed miRNAs. In BRAFmut melanoma, 37 microRNAs were differentially expressed: 11 overexpressed and 26 underexpressed. Four miRNAs showed elevated expression in both melanoma groups. Among them, miR-146a-5p and miR-4286 demonstrated the highest elevation, especially in BRAFmut tumors. We focused further on their targeted genes. Conclusion: This study demonstrates significant alterations in the miRNA expression profile in metastatic melanoma and highlights the potential of miR-146a-5p and miR-4286 as key regulators of tumor biology.

## Linked entities

- **Genes:** BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673]
- **Diseases:** melanoma (MONDO:0005105)

## Full-text entities

- **Genes:** WASF2 (WASP family member 2) [NCBI Gene 10163] {aka IMD2, SCAR2, WASF4, WAVE2, dJ393P12.2}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, ACTB (actin beta) [NCBI Gene 60] {aka BKRNS, BNS, BRWS1, CSMH, DDS1, PS1TP5BP1}, MIR4488 (microRNA 4488) [NCBI Gene 100616470] {aka mir-4488}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MAP3K1 (mitogen-activated protein kinase kinase kinase 1) [NCBI Gene 4214] {aka MAPKKK1, MEKK, MEKK 1, MEKK1, SRXY6}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, RPL19 (ribosomal protein L19) [NCBI Gene 6143] {aka L19, eL19}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, RUNX3 (RUNX family transcription factor 3) [NCBI Gene 864] {aka AML2, CBFA3, PEBP2aC}, MIR451A (microRNA 451a) [NCBI Gene 574411] {aka MIR451, MIRN451, hsa-mir-451, hsa-mir-451a, mir-451a}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, HDAC3 (histone deacetylase 3) [NCBI Gene 8841] {aka HD3, KDAC3, RPD3, RPD3-2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, TRAF6 (TNF receptor associated factor 6) [NCBI Gene 7189] {aka MGC:3310, RNF85}, MIR4286 (microRNA 4286) [NCBI Gene 100422982] {aka mir-4286}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, RPLP0 (ribosomal protein lateral stalk subunit P0) [NCBI Gene 6175] {aka L10E, LP0, P0, PRLP0, RPP0, uL10}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SMAD4 (SMAD family member 4) [NCBI Gene 4089] {aka DPC4, JIP, MADH4, MYHRS}, B2M (beta-2-microglobulin) [NCBI Gene 567] {aka AMYLD6, IMD43, MHC1D4}, TGFBR2 (transforming growth factor beta receptor 2) [NCBI Gene 7048] {aka AAT3, FAA3, LDS1B, LDS2, LDS2B, MFS2}, IRAK1 (interleukin 1 receptor associated kinase 1) [NCBI Gene 3654] {aka IRAK, pelle}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}
- **Diseases:** inflammation (MESH:D007249), skin and uveal melanoma (MESH:C536494), metastatic (MESH:D000092182), Cancer (MESH:D009369), ulcerated primary cutaneous melanoma (MESH:C562393), Melanoma (MESH:D008545), nodal (MESH:D013611), metastasis (MESH:D009362), injury to (MESH:D014947)
- **Chemicals:** glucose (MESH:D005947), mineral oil (MESH:D008899), paraffin (MESH:D010232), formalin (MESH:D005557), xylene (MESH:D014992), biotin (MESH:D001710)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** BRAFV600E, V600D, V600K

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025385/full.md

---
Source: https://tomesphere.com/paper/PMC13025385